At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 37 enrolled
Drug / intervention
Imatinib +1 moredrug
Likely dose
Docetaxel plus imatinib (specific doses not stated in available text)AI-extracted
Key inclusion· 5
- ✓Metastatic breast cancer confirmed by biopsy
- ✓No more than one prior chemotherapy regimen for metastatic breast cancer
- ✓Able to perform activities of daily living with minimal assistance
- ✓Adequate bone marrow, liver and kidney function
Key exclusion· 9
- ✕Moderate to severe peripheral neuropathy
- ✕Uncontrolled blood pressure or uncontrolled heart beat irregularities
- ✕Diabetes Mellitus with fasting blood sugar greater than 200 mg%
- ✕Significant heart disease within the prior 6 months
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Trial of Docetaxel Plus Imatinib Mesylate in Metastatic Breast Cancer
In Brief
A Phase 2 clinical trial evaluating Imatinib and Docetaxel for Breast Cancer. Completed, enrolled 37 participants across 6 sites.
Detailed Summary
This trial evaluates the novel combination of docetaxel with imatinib as first or second line therapy in advanced breast cancer with the aim of achieving higher effectiveness and potentially reducing side effects.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer
CountriesUnited States
CollaboratorsNovartis, Aventis Pharmaceuticals
Timeline
Phase 2CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartMay 2005
First PostedSep 2005
Primary CompletionMay 2008
Study CompletionJan 2009
TodayJul 2026
First PostedSep 19, 2005
Enrollment StartMay 1, 2005
Primary CompletionMay 1, 2008
Study CompletionJan 1, 2009
TodayJul 2, 2026
Enrollment to primary: 3 yearsPosted 20.8 years ago
Interventions
Imatinibdrug
Imatinib
Docetaxeldrug
Docetaxel